CD274 and non-small cell lung carcinoma: On the contrary, another exploratory analysis reported an association between higher tTMB levels and improved clinical outcome with pembrolizumab monotherapy in PD-L1-positive NSCLC patients [31], which suggested a synergism with both biomarkers that should be explored in prospective cohorts.